{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '122', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'potential fraud, scientific/research misconduct, privacy incidents/breaches or Clinical Trial-related', 'Significant Quality Issues are reported, such matters are investigated. When necessary, appropriate corrective', 'and/or preventative actions are defined and regulatory authorities and/or ethics review committees are', 'notified.', 'B. Publication and Authorship', 'Regardless of trial outcome, MSD commits to publish primary and secondary results of its registered trials of', 'marketed products in which treatment is assigned, according to the prespecified plans for data analysis. To the', 'extent scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important', 'to patients, physicians, and payers. Some early phase or pilot trials are intended to be hypothesis-generating rather', 'than hypothesis testing, in such cases, publication of results may not be appropriate since the trial may be', 'underpowered and the analyses complicated by statistical issues such as multiplicity.', \"MSD's policy on authorship is consistent with the recommendations published by the International Committee\", 'of', 'Medical Journal Editors (ICMJE). In summary, authorship should reflect significant contribution to the design and', 'conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named', 'authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in', 'publications.', 'III. Participant Protection', 'A. Ethics Committee Review (Institutional Review Board IRB]/Independent Ethics Committee [IEC])', 'All clinical trials will be reviewed and approved by an IRB/IEC before being initiated at each site. Significant', 'changes or revisions to the protocol will be approved by the ethics committee prior to implementation, except', 'changes required urgently to protect participant safety that may be enacted in anticipation of ethics committee', 'approval. For each site, the ethics committee and MSD will approve the participant informed consent form.', 'B. Safety', 'The guiding principle in decision-making in clinical trials is that participant welfare is of primary importance.', 'Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At', 'a minimum, trial designs will take into account the local standard of care.', 'All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is', 'obtained. Participants may withdraw from an MSD trial at any time, without any influence on their access to, or', 'receipt of, medical care that may otherwise be available to them.', 'C. Confidentiality', 'MSD is committed to safeguarding participant confidentiality, to the greatest extent possible, as well as all', 'applicable data protection rights. Unless required by law, only the investigator, Sponsor (or individuals acting on', 'behalf of MSD), ethics committee, and/or regulatory authorities will have access to confidential medical records', 'that might identify the participant by name.', 'D. Genomic Research', 'Genomic research will only be conducted in accordance with a protocol and informed consent authorized by an', 'ethics committee.', 'IV. Financial Considerations', 'A. Payments to Investigators', \"Clinical trials are time- and labor-intensive. It is MSD's policy to compensate investigators (or the sponsoring\", 'institution) in a fair manner for the work performed in support of MSD trials. MSD does not pay incentives to', 'enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be', 'made to compensate for the time spent in extra recruiting efforts.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '123', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'MSD does not pay for participant referrals. However, MSD may compensate referring physicians for time spent', 'on chart review to identify potentially eligible participants.', 'B. Clinical Research Funding', 'Informed consent forms will disclose that the trial is sponsored by MSD and that the investigator or sponsoring', 'institution is being paid or provided a grant for performing the trial. However, the local ethics committee may', 'wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As', 'noted above, all publications resulting from MSD trials will indicate MSD as a source of funding.', 'C. Funding for Travel and Other Requests', 'Funding of travel by investigators and support staff (eg, to scientific meetings, investigator meetings, etc.) will be', 'consistent with local guidelines and practices.', 'V. Investigator Commitment', \"Investigators will be expected to review MSD's Code of Conduct as an appendix to the trial protocol, and in signing the\", 'protocol, agree to support these ethical and scientific standards.', '10.1.2', 'Financial Disclosure', 'Financial Disclosure requirements are outlined in the US Food and Drug Administration', 'Regulations, Financial Disclosure by Clinical Investigators (21 CFR Part 54). It is the', \"Sponsor's responsibility to determine, based on these regulations, whether a request for\", \"Financial Disclosure information is required. It is the investigator's/subinvestigator's\", 'responsibility to comply with any such request.', 'The investigator/subinvestigator(s) agree, if requested by the Sponsor in accordance with 21', 'CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to', 'allow for the submission of complete and accurate certification and disclosure statements.', 'The investigator/subinvestigator(s) further agree to provide this information on a', 'Certification/Disclosure Form, commonly known as a financial disclosure form, provided by', 'the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this', 'information to the Sponsor in the United States for these purposes. This may involve the', 'transmission of information to countries that do not have laws protecting personal data.', '10.1.3', 'Data Protection', 'Participants will be assigned a unique identifier by the Sponsor. Any participant records or', 'datasets that are transferred to the Sponsor will contain the identifier only; participant names', 'or any information that would make the participant identifiable will not be transferred.', 'The participant must be informed that his/her personal study-related data will be used by the', 'Sponsor in accordance with local data protection law. The level of disclosure must also be', 'explained to the participant.', 'The participant must be informed that his/her medical records may be examined by Clinical', 'Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by', 'appropriate IRB/IEC members, and by inspectors from regulatory authorities.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}